619 results match your criteria fluvoxamine review


Drug interaction between a selective serotonin reuptake inhibitor and a triptan leading to serotonin toxicity: a case report and review of the literature.

J Med Case Rep 2021 Jul 26;15(1):371. Epub 2021 Jul 26.

Redcliffe Hospital, Anzac Avenue, Redcliffe, QLD, 4020, Australia.

Background: Serotonin toxicity is a known side effect of selective serotonin reuptake inhibitors and has previously also been described as a possible side effect of 5-hydroxytryptamine receptor agonist (triptan) medications. However, the literature is conflicted about the risk of developing serotonin toxicity as a result of drug interaction between selective serotonin reuptake inhibitors and triptans.

Case Presentation: A 30-year-old Caucasian woman with a history of depression on regular fluvoxamine presented to the emergency department with right-sided facial and lower limb twitching. Read More

View Article and Full-Text PDF

Are central nervous system drugs displaying anti-inflammatory activity suitable for early treatment of COVID-19?

Folia Neuropathol 2021 ;59(2):113-120

Department of Neurology, Medical University of Lublin, Lublin, Poland.

The majority of COVID-19 cases are only mildly or moderately symptomatic, but in some patients excessive inflammatory response becomes the dominant factor of disease progression to the advanced stage, with high mortality. Treatment with anti-inflammatory drugs either does not prevent disease progression (non-steroidal anti-inflammatory drugs [NSAIDs], colchicine), or is recommended only at the advanced disease stage (dexamethasone). Fluvoxamine and amantadine are drugs used to treat neurological and psychiatric diseases. Read More

View Article and Full-Text PDF
January 2021

Pharmacological Treatment of Patients with Mild to Moderate COVID-19: A Comprehensive Review.

Int J Environ Res Public Health 2021 07 5;18(13). Epub 2021 Jul 5.

Department of Medicine, University of Ribeirão Preto, 2201 Costabile Romano, Ribeirão Preto 14096-385, Brazil.

Mild to moderate COVID-19 can be found in about 80% of patients. Although mortality is low, mild to moderate COVID-19 may progress to severe or even critical stages in about one week. This poses a substantial burden on the health care system, and ultimately culminates in death or incapacitation and hospitalization. Read More

View Article and Full-Text PDF

Relative frequency of drug-induced sleep disorders for 32 antidepressants in a large set of Internet user reviews.

Sleep 2021 Jul 12. Epub 2021 Jul 12.

Faculty of Pharmacy, University of Strasbourg, France.

Study Objectives: It is known that antidepressant drugs can induce sleep disorders in patients, but little data exist about high or low-risk molecules. The aim was to study the frequency of antidepressant drugs-induced sleep disorders (DISD) by molecule.

Methods: 77,391 patient comments for 32 antidepressant drugs were collected from drug review websites and screened for DISD. Read More

View Article and Full-Text PDF

Drugs that offer the potential to reduce hospitalization and mortality from SARS-CoV-2 infection: The possible role of the sigma-1 receptor and autophagy.

Expert Opin Ther Targets 2021 Jul 15:1-15. Epub 2021 Jul 15.

Natural Products for Neuroprotection and Anti-ageing Research Unit, Chulalongkorn University, Bangkok, Thailand.

: Despite the availability of new vaccines for SARS-CoV-2, there has been slow uptake and problems with supply in some parts of the world. Hence, there is still a necessity for drugs that can prevent hospitalization of patients and reduce the strain on health care systems. Drugs with sigma affinity potentially provide protection against the most severe symptoms of SARS-COV-2 and could prevent mortality via interactions with the sigma-1 receptor. Read More

View Article and Full-Text PDF

Interventions in an Ambulatory Setting to Prevent Progression to Severe Disease in Patients With COVID-19: A Systematic Review.

Ann Pharmacother 2021 Jun 22:10600280211028242. Epub 2021 Jun 22.

Health Information and Quality Authority, Dublin, Ireland.

Objective: To conduct a systematic review on the effectiveness and safety of pharmacological and nonpharmacological interventions, in the ambulatory setting, aimed at preventing severe disease in patients with COVID-19.

Data Sources: Electronic databases (PubMed, EMBASE, and EuropePMC) were searched on January 6, 2021.

Study Selection And Data Extraction: A systematic review was conducted, adhering to PRISMA guidelines. Read More

View Article and Full-Text PDF

A review on post-traumatic stress disorder (PTSD): "Symptoms, Therapies and Recent Case Studies".

Curr Mol Pharmacol 2021 May 25. Epub 2021 May 25.

Department of School of Pharmacy, Abhilashi University, Chail Chowk, tehsil Chachyot, Mandi, Himachal Pradesh 175028, India.

Post-traumatic stress disorder (PTSD), previously known as battle fatigue syndrome or shell shock, is a severe mental disturbance condition that is normally triggered by the experience of some frightening/scary events or trauma where a person undergoes some serious physical or mental harm or threatened. PTSD is a long-life effect of the continuous occurrence of traumatic conditions which, leading the production of feelings of helplessness, intense fear, and horror in the person. There are various examples of events that can cause PTSD, such as physical, mental, or sexual assault at home or working place by others, unexpected death of a loved one, an accidental event, war, or some kind of natural disaster. Read More

View Article and Full-Text PDF

Beneficial and harmful effects of antidepressants versus placebo, 'active placebo', or no intervention for adults with major depressive disorder: a protocol for a systematic review of published and unpublished data with meta-analyses and trial sequential analyses.

Syst Rev 2021 05 25;10(1):154. Epub 2021 May 25.

Copenhagen Trial Unit, Centre for Clinical Intervention Research, The Capital Region, Copenhagen University Hospital -- Rigshospitalet, Blegdamsvej 9, 2100, Copenhagen, Denmark.

Background: Major depressive disorder is one of the most common, burdensome, and costly psychiatric disorders worldwide. Antidepressants are frequently used to treat major depressive disorder. It has been shown repeatedly that antidepressants seem to reduce depressive symptoms with a statistically significant effect, but the clinical importance of the effect sizes seems questionable. Read More

View Article and Full-Text PDF

Comparative efficacy and acceptability of antidepressants and benzodiazepines for the treatment of panic disorder: A systematic review and network meta-analysis.

Asian J Psychiatr 2021 Jun 3;60:102664. Epub 2021 May 3.

School of Pharmacy, Southwest Medical University, Luzhou, Sichuan, 646000, China.

Objective: This systematic review aims to assess the efficacy and acceptability of the different types of antidepressants and benzodiazepines for the treatment of panic disorder (PD) in adult patients.

Methods: PubMed, Web of Science, EMBASE, MEDLINE, the Cochrane Library, and ClinicalTrials.gov were searched for randomized controlled trials (RCTs) published between 1995 and 2020 on the use of antidepressants and benzodiazepines for the treatment of PD. Read More

View Article and Full-Text PDF

Fluvoxamine: A Review of Its Mechanism of Action and Its Role in COVID-19.

Front Pharmacol 2021 20;12:652688. Epub 2021 Apr 20.

GlobalCures, Inc., Newton, MA, United States.

Fluvoxamine is a well-tolerated, widely available, inexpensive selective serotonin reuptake inhibitor that has been shown in a small, double-blind, placebo-controlled, randomized study to prevent clinical deterioration of patients with mild coronavirus disease 2019 (COVID-19). Fluvoxamine is also an agonist for the sigma-1 receptor, through which it controls inflammation. We review here a body of literature that shows important mechanisms of action of fluvoxamine and other SSRIs that could play a role in COVID-19 treatment. Read More

View Article and Full-Text PDF

Revisiting monoamine oxidase inhibitors for the treatment of depressive disorders: A systematic review and network meta-analysis.

J Affect Disord 2021 03 13;282:1153-1160. Epub 2021 Jan 13.

Faillace Department of Psychiatry and Behavioral Sciences, Department of Psychiatry and Behavioral Sciences, The University of Texas Health Science Center at Houston, 1941 East Rd, Houston, TX 77054; Faillace Department of Psychiatry and Behavioral Sciences, Depression Research Program, Department of Psychiatry and Behavioral Sciences, The University of Texas Health Science Center at Houston, 1941 East Rd, Houston, TX 77054; Houston Methodist Research Institute, Institute for Academic Medicine, 6670 Bertner St., Houston, TX 77030, USA.

Background: Monoamine oxidase inhibitors (MAOIs) were the first class of modern antidepressants; however, they are under-utilized as compared to the newer antidepressants.

Methods: In this systematic review, network meta-analysis was used to investigate the comparative efficacy and acceptability of MAOIs for depressive disorders. Overall, the network meta-analysis included 52 double-blind, randomized controlled trials (RCTs) that compared 14 antidepressants or placebo. Read More

View Article and Full-Text PDF

High-Dose Fluvoxamine Augmentation to Clozapine in Treatment-Resistant Psychosis.

J Clin Psychopharmacol 2021 Mar-Apr 01;41(2):186-190

From the Non-invasive Neurostimulation Therapies Laboratory.

Background: Although clozapine is the gold standard for treatment-resistant schizophrenia, more than 30% of patients remain unresponsive to clozapine monotherapy and may benefit from augmentation strategies. Fluvoxamine augmentation of clozapine may be beneficial in treatment resistance because of pharmacokinetic interactions, allowing for lower clozapine dosages with higher clozapine serum levels and an increased clozapine-to-norclozapine ratio, which can modify adverse effects. An augmentation strategy using higher fluvoxamine doses may also improve persistent negative, anxiety, and obsessive-compulsive symptoms through fluvoxamine's serotonergic activity. Read More

View Article and Full-Text PDF
February 2021

A narrative review of risk factors and interventions for cancer-related cognitive impairment.

Authors:
Lu Bai Enyan Yu

Ann Transl Med 2021 Jan;9(1):72

Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Hangzhou, China.

Cancer-related cognitive impairment (CRCI) refers to a series of cognitive impairment symptoms associated with alternations in brain structure and function, caused by a non-central nervous system malignant tumor and its related treatment. CRCI may present as memory loss, impaired concentration, difficulty in multitasking and word retrieval, and reduced comprehension speed. CRCI has become one of the prevalent factors that compromise the quality of life for cancer survivors. Read More

View Article and Full-Text PDF
January 2021

Gastrointestinal side effects associated with antidepressant treatments in patients with major depressive disorder: A systematic review and meta-analysis.

Prog Neuropsychopharmacol Biol Psychiatry 2021 Jul 5;109:110266. Epub 2021 Feb 5.

Department of Biomedical and Neuromotor Sciences, University of Bologna, Bologna, Italy. Electronic address:

Gastrointestinal side effects (SEs) are frequently observed in patients with major depressive disorder (MDD) while taking antidepressants and may lead to treatment discontinuation. The aim of this meta-analysis is to provide quantitative measures on short-term rates of gastrointestinal SEs in MDD patients treated with second-generation antidepressants. An electronic search of the literature was conducted by using MEDLINE, ISI Web of Science - Web of Science Core Collection, and Cochrane Library databases. Read More

View Article and Full-Text PDF

Treatment of Aggression in Adults with Autism Spectrum Disorder: A Review.

Authors:
David S Im

Harv Rev Psychiatry 2021 Jan-Feb 01;29(1):35-80

From the University of Michigan Hospital, Department of Psychiatry, University of Michigan Medical School.

Background: Autism spectrum disorder (ASD) is a neurodevelopmental disorder characterized by markedly impaired social interaction, impaired communication, and restricted/repetitive patterns of behavior, interests, and activities. In addition to challenges caused by core symptoms, maladaptive behaviors such as aggression can be associated with ASD and can further disrupt functioning and quality of life. For adults with ASD, these behaviors can portend adverse outcomes (e. Read More

View Article and Full-Text PDF
January 2021

Repurposing of CNS drugs to treat COVID-19 infection: targeting the sigma-1 receptor.

Authors:
Kenji Hashimoto

Eur Arch Psychiatry Clin Neurosci 2021 Mar 5;271(2):249-258. Epub 2021 Jan 5.

Division of Clinical Neuroscience, Chiba University Center for Forensic Mental Health, 1-8-1 Inohana, Chiba, 260-8670, Japan.

The novel coronavirus disease 2019 (COVID-19) is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The escalating number of SARS-CoV-2-infected individuals has conferred the viral spread with the status of global pandemic. However, there are no prophylactic or therapeutic drugs available on the market to treat COVID-19, although several drugs have been approved. Read More

View Article and Full-Text PDF

Metabolism and Mechanism of Human Cytochrome P450 Enzyme 1A2.

Curr Drug Metab 2021 ;22(1):40-49

National Reference Laboratory of Veterinary Drug Residues (HZAU) and MAO Key Laboratory for Detection of Veterinary Drug Residues, Huazhong Agricultural University, Wuhan, Hubei 430070, China.

Human cytochrome P450 enzyme 1A2 (CYP1A2) is one of the most important cytochrome P450 (CYP) enzymes in the liver, accounting for 13% to 15% of hepatic CYP enzymes. CYP1A2 metabolises many clinical drugs, such as phenacetin, caffeine, clozapine, tacrine, propranolol, and mexiletine. CYP1A2 also metabolises certain precarcinogens such as aflatoxins, mycotoxins, nitrosamines, and endogenous substances such as steroids. Read More

View Article and Full-Text PDF
January 2021

Verification of a cocktail approach for quantitative drug-drug interaction assessment: a comparative analysis between the results of a single drug and a cocktail drug.

Xenobiotica 2021 Apr 13;51(4):404-412. Epub 2021 Jan 13.

Departments of Pharmacy Practice and Science, School of Pharmaceutical Sciences, University of Shizuoka, Shizuoka, Japan.

A cocktail approach is a method to comprehensively evaluate the activity of cytochrome P450 enzymes (CYPs) by co-administering multiple CYP substrates. This is the first report that compares the results from a cocktail study to a single substrate separate administration study (single study) with concomitant administration of CYP inducers/inhibitors. The validity of a cocktail study for use as a quantitative drug-drug interactions (DDIs) assessment was evaluated. Read More

View Article and Full-Text PDF

Antidepressant transfer into amniotic fluid, umbilical cord blood & breast milk: A systematic review & combined analysis.

Prog Neuropsychopharmacol Biol Psychiatry 2021 Apr 2;107:110228. Epub 2021 Jan 2.

Department of Clinical Pharmacology, St Olav University Hospital, Trondheim, Norway; Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway.

Objective: Data regarding the ability of antidepressants to enter fetal, newborn and infant fluids have become gradually available, but mechanisms of antidepressant transfer remain poorly understood. Here we calculated penetration ratios in an array of matrices from combined samples of pregnant/breastfeeding women taking antidepressants.

Method: We performed a systematic literature search of PubMed and EMBASE to identify studies with concentrations of antidepressants from maternal blood, amniotic fluid, umbilical cord blood and/or breast milk. Read More

View Article and Full-Text PDF

Exploring the utility of RDoC in differentiating effectiveness amongst antidepressants: A systematic review using proposed psychometrics as the unit of analysis for the Negative Valence Systems domain.

Authors:
Andrew Hui

PLoS One 2020 16;15(12):e0243057. Epub 2020 Dec 16.

NorthWestern Mental Health, The Royal Melbourne Hospital, Melbourne, Australia.

Background: RDoC conceptualises psychopathology as neurobiologically-rooted behavioural psychological "constructs" that span dimensionally from normality to pathology, but its clinical utility remains controversial.

Aim: To explore RDoC's potential clinical utility by examining antidepressant effectiveness through Negative Valence Systems (NVS) domain constructs.

Method: A systematic review was conducted on Web of Science, MEDLINE, EMBASE and PsycINFO for antidepressant trials that included psychometric instruments assessed by Watson, Stanton & Clark (2017) to represent NVS constructs of Acute Threat, Potential Threat and Loss. Read More

View Article and Full-Text PDF
January 2021

Association of CYP2C19 and CYP2D6 Poor and Intermediate Metabolizer Status With Antidepressant and Antipsychotic Exposure: A Systematic Review and Meta-analysis.

JAMA Psychiatry 2021 Mar;78(3):270-280

Department of Physiology, Faculty of Pharmacy, University of Belgrade, Belgrade, Serbia.

Importance: Precise estimation of the drug metabolism capacity for individual patients is crucial for adequate dose personalization.

Objective: To quantify the difference in the antipsychotic and antidepressant exposure among patients with genetically associated CYP2C19 and CYP2D6 poor (PM), intermediate (IM), and normal (NM) metabolizers.

Data Sources: PubMed, Clinicaltrialsregister. Read More

View Article and Full-Text PDF

Application of antidepressants in depression: A systematic review and meta-analysis.

J Clin Neurosci 2020 Oct 19;80:169-181. Epub 2020 Aug 19.

Fujian Provincial Key Laboratory of Neurodegenerative Disease and Aging Research, Institute of Neuroscience, School of Medicine, Xiamen University, Xiamen, Fujian 361102, PR China. Electronic address:

Background: The type and quantities of antidepressants are increasing, but the efficacy and safety of first-line and emerging drugs vary between studies. In this article, we estimated the efficacy and safety of first-line and emerging antidepressants (anti-inflammatory drugs and ketamine).

Method: ystematic search of EMBASE, ERIC, MEDLINE, psycARTICLES, and psycINFO without language restriction for studies on the depression, depressive symptoms, antidepressants, fluoxetine (Prozac), paroxetine, escitalopram, sertraline, fluvoxamine, venlafaxine, duloxetine, NSAIDs, anti-cytokine drugs or pioglitazone published before May 1st, 2019. Read More

View Article and Full-Text PDF
October 2020

Selective serotonin reuptake inhibitors and the risk of congenital anomalies: a systematic review of current meta-analyses.

Authors:
Faruk Uguz

Expert Opin Drug Saf 2020 Dec 12;19(12):1595-1604. Epub 2020 Oct 12.

Department of Psychiatry, Meram Faculty of Medicine, Necmettin Erbakan University , Konya, Turkey.

A review of current meta-analyses examining the relationship between maternal use of selective serotonin reuptake inhibitors (SSRIs) during pregnancy and congenital anomalies. PubMed was searched for meta-analyses published in English language between January 2010 and April 2020 by using the following combinations of key words: A total of 15 meta-analyses met the search criteria. These meta-analyses consistently suggested a significant positive association between the use of SSRIs in general and paroxetine and fluoxetine in particular and the risk of major congenital anomalies. Read More

View Article and Full-Text PDF
December 2020

Update on Pharmacotherapy in Psychodermatological Disorders.

Indian Dermatol Online J 2020 May-Jun;11(3):307-318. Epub 2020 May 10.

Department of Dermatology, Kasturba Medical College, Manipal, Manipal Academy of Higher Education, Udupi, Karnataka, India.

Psychodermatological (PD) conditions encountered in dermatologic practice include primary psychiatric conditions such as delusions of parasitosis or secondary psychiatric conditions such as anxiety and depression due to dermatologic disease. The psychotropics include antipsychotic agents, anti-anxiety agents, antidepressants, and miscellaneous drugs such as anti convulsants. Anti psychotics are further divided into first-generation and second-generation drugs. Read More

View Article and Full-Text PDF

Selective serotonin reuptake inhibitors in major depression disorder treatment: an umbrella review on systematic reviews.

Int J Psychiatry Clin Pract 2020 Nov 15;24(4):357-370. Epub 2020 Jul 15.

Health Human Resources Research Center, School of Management and Medical Informatics, Shiraz University of Medical Sciences, Shiraz, Iran.

Background: Major depressive disorder (MDD) is a common mental problem and one of the leading causes of disability worldwide. SSRIs are the most commonly prescribed types of antidepressants which are called Selective Serotonin Reuptake Inhibitors and used as a primary therapeutic intervention in MDD. This umbrella review aimed to assess the efficacy and tolerability of selected SSRIs. Read More

View Article and Full-Text PDF
November 2020

Adjunctive Fluvoxamine for Schizophrenia: A Meta-analysis of Randomized Double-Blind, Placebo-Controlled Trials.

J Clin Psychopharmacol 2020 Jul/Aug;40(4):386-390

Unit of Psychiatry, Institute of Translational Medicine, Faculty of Health Sciences, & Center for Cognition and Brain Sciences, University of Macau, Macao SAR, China.

Background: This was a meta-analysis of double-blind, randomized controlled trials that examined the therapeutic effects and tolerability of adjunctive fluvoxamine versus placebo for schizophrenia.

Methods: The Review Manager, Version 5.3, was used to analyze data. Read More

View Article and Full-Text PDF
January 2021

Similarities and dissimilarities in the effects of benzodiazepines and specific serotonin reuptake inhibitors (SSRIs) in the defensive marble burying test: A systematic review and meta-analysis.

Eur Neuropsychopharmacol 2020 07 23;36:38-49. Epub 2020 May 23.

School of Behavioral Sciences, Tel Aviv-Yaffo Academic College, Tel-Aviv, Israel.

One problem areas of animal models and tests for neuropsychiatric disorders is unclear reproducibility, including both internal and external validity. One way to examine external validity is with systematic reviews and meta-analyses, a standard practice in clinical research that is relatively neglected in preclinical research. Considering the need to evaluate the validity and reproducibility of frequently used animal models, this study presents a meta-analysis of the effects of prototypic benzodiazepines and specific serotonin reuptake inhibitors (SSRIs) in the mouse defensive marble burying test (MBT). Read More

View Article and Full-Text PDF

Meta-analysis: Pharmacologic Treatment of Restricted and Repetitive Behaviors in Autism Spectrum Disorders.

J Am Acad Child Adolesc Psychiatry 2021 01 6;60(1):35-45. Epub 2020 May 6.

Yale Child Study Center, Yale University School of Medicine, New Haven, Connecticut.

Objective: To examine the efficacy of pharmacological treatments for restricted and repetitive behaviors (RRB) in autism spectrum disorders (ASD).

Method: We searched PubMed, Embase, and CENTRAL to identify all double-blind, randomized, placebo-controlled trials that examined the efficacy of pharmacological agents in the treatment of ASD and measured RRB as an outcome. Our primary outcome was the standardized mean difference in rating scales of RRB. Read More

View Article and Full-Text PDF
January 2021